Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma

Durvalumab 1500 mg via intravenous (IV) infusion every 3 weeks for up to 8 cycles

A single dose of tremelimumab at 300mg IV is given on C1.

Gemcitabine is dosed at 1000 mg/m2 IV on day (D)1 and D8 of each cycle.

Cisplatin is dosed at 25mg/m2 on D1 and D8 of each cycle.

If the tumor is evaluated to be resectable (as defined as successfully treated stage II (tumor shrink away from vessels), stage IIIA (tumor shrink away from visceral peritoneum), stage IIIB (N1 disease no longer pathologically enlarged) after C4 or C8, then the patient may proceed with surgical tumor resection.